Cagrilintide 10mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

Cagrilintide is a long-acting amylin analog studied for appetite control and weight management[1] — it imitates the satiety hormone amylin to blunt hunger and slow gastric emptying[2]. A long action profile supports a single weekly subcutaneous injection, and a stepwise dose increase helps keep tolerability high while the body adjusts[3][4]. For research and educational use only.

Two options: 2.0 mL bacteriostatic water per 10 mg vial → 5 mg/mL (gradual), or 1.0 mL → 10 mg/mL (advanced).
0.25–4.5 mg once weekly, raised in phases over several weeks.
At 5 mg/mL, 1 mg = 0.20 mL = 20 units; at 10 mg/mL, 1 mg = 0.10 mL = 10 units on a U-100 syringe.
Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Important: Read the Prep & Injection Guide first — it covers the preparation and safety basics that every protocol on this site assumes.

Dosing & Reconstitution Guide

Two reconstitution strategies with accurate weekly dosing, step by step

Advanced / Aggressive Approach (1 mL = 10 mg/mL)

Week(s)	Weekly Dose (mg)	Total weekly volume (U-100 units / mL)
Weeks 1–4	0.6 mg	6 units (0.06 mL)
Weeks 5–8	1.2 mg	12 units (0.12 mL)
Weeks 9–12	2.4 mg	24 units (0.24 mL)
Weeks 13–16 (Optional)	4.5 mg	45 units (0.45 mL)

Reconstitute: Add 2.0 mL bacteriostatic water to one 10 mg vial → final concentration: 5 mg/mL.
Typical weekly range: 0.25–2.4 mg once weekly, titrated slowly over 16 weeks.
Easy measuring: At 5 mg/mL, 1 mg = 0.20 mL = 20 units on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Frequency: one subcutaneous injection each week. The gentle ramp from 0.25 mg up to 2.4 mg mirrors the phase 2 dose-finding schedule that achieved meaningful weight loss while keeping nausea and other gastrointestinal effects manageable[1][4]. Holding each step for two to four weeks before advancing gives the body time to adapt.
Reconstitute: Add 1.0 mL bacteriostatic water to one 10 mg vial → final concentration: 10 mg/mL.
Typical weekly range: 0.6–4.5 mg once weekly for those titrating to higher doses.
Easy measuring: At 10 mg/mL, 1 mg = 0.10 mL = 10 units on a U-100 insulin syringe.
Note: A 4.5 mg weekly dose draws about 45 units (0.45 mL) — roughly half the reconstituted vial.
Higher concentration: mixing to 10 mg/mL keeps injection volumes small even at the top of the range — useful when titrating toward 4.5 mg, the dose linked with the largest weight reductions in early trials[4]. Because a 4.5 mg dose uses about half the reconstituted vial, plan vial supply accordingly.

Reconstitution Steps

Pull the chosen volume of bacteriostatic water (2.0 mL for 5 mg/mL, or 1.0 mL for 10 mg/mL) into a sterile syringe.

Release it slowly against the vial’s inner wall to avoid foaming.
Swirl or roll gently until fully dissolved — don’t shake hard.
Note the mixing date and store at 2–8 °C (35.6–46.4 °F), shielded from light.
Both concentrations keep every weekly dose within a single U-100 syringe (≤100 units / 1.0 mL). Pick the gradual 5 mg/mL mix for fine, low-dose steps, or the 10 mg/mL mix for compact volumes at higher doses.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week course of weekly injections, titrated gradually up to the maintenance dose.

A single 10 mg vial covers the early, low-dose weeks; higher doses use more.
8 weeks (0.25→1.0 mg/wk): ~1 vial
12 weeks (gradual to 1.7 mg/wk): ~2 vials
16 weeks (gradual to 2.4–4.5 mg/wk): ~3 vials
Per week: 1 syringe (once-weekly dosing)
12 weeks: 12 syringes
24 weeks: 24 syringes
48 weeks: 48 syringes
Use 2.0 mL (gradual) or 1.0 mL (advanced) per vial for reconstitution.
8 weeks (1 vial): 1–2 mL → 1 × 10 mL bottle
12 weeks (2 vials): 2–4 mL → 1 × 10 mL bottle
16 weeks (3 vials): 3–6 mL → 1 × 10 mL bottle
One for the vial stopper + one for the injection site each week.
Per week: 2 swabs
12 weeks: 24 swabs → 1 × 100-count box
24 weeks: 48 swabs → 1 × 100-count box
48 weeks: 96 swabs → 1 × 100-count box

Protocol Overview

The once-weekly regimen at a glance, drawn from published dose-finding research.

▪Goal: Support appetite regulation and weight management by mimicking amylin’s satiety signalling[1][3].
▪Schedule: One subcutaneous injection a week across an 8–16 week course, with the dose raised in phases.
▪Dose Range: From 0.25 mg up to about 4.5 mg weekly in advanced protocols, increased gradually[1].
▪Reconstitution: 2.0 mL water per 10 mg vial gives 5 mg/mL for fine low-dose steps; 1.0 mL gives 10 mg/mL for compact higher doses.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.

Dosing Protocol

A suggested once-weekly approach, with either a gradual or a more aggressive escalation.

▪Start: Begin at 0.25 mg (gradual) or 0.6 mg (advanced) weekly to settle tolerability[1][4].
▪Escalation: Step the dose up every few weeks — e.g. 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg on the gradual track[1].
▪Maximum: Up to roughly 4.5 mg weekly in advanced protocols, the dose tied to the greatest weight loss in early trials[4].
▪Frequency: Once a week, subcutaneous — holding the same day and time each week aids consistency.
▪Cycle Length: Typically 8–16 weeks; extend as needed for ongoing management.
▪Timing: Any steady weekly schedule works; change the injection site with each dose.

Storage Instructions

Correct storage is what preserves the peptide’s stability and potency.

▪Lyophilized: Hold at −20 °C (−4 °F) or colder for long-term keeping; shield from moisture and light[11][12].
▪Reconstituted: Chill at 2–8 °C (35.6–46.4 °F) as soon as it’s mixed and use within 2–4 weeks to keep stability and potency[11].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form; keep the mixed solution clear of heat and direct sun.
▪Aliquoting: To store beyond 4 weeks, divide the unused portion into aliquots and freeze; steer clear of repeated freeze–thaw cycles, which cause degradation[12].

Important Notes

Practical points that keep weekly administration safe and consistent.

▪Weekly consistency: Lock in one day and time for the weekly injection and keep to it for the whole protocol.
▪Gradual titration is essential: Starting low (around 0.25 mg weekly) and stepping up slowly markedly lowers the odds of early gastrointestinal effects[4].
▪Syringe use: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward[14].
▪Injection site rotation: Move sites week to week (abdomen, thighs, upper arms), keeping each shot at least 1 inch from the last to limit irritation and prevent lipohypertrophy[15].
▪Large volumes: When a dose needs more than 1.0 mL (>100 units), divide it across sites or draw from more than one reconstituted vial.
▪Side-effect monitoring: Mild nausea or stomach upset is normal while escalating; if it becomes notable, hold the current dose longer before stepping up.

How This Works

Cagrilintide is a long-acting amylin analog. Amylin is a peptide hormone the pancreas co-secretes with insulin; it signals fullness, slows the rate at which the stomach empties, and helps reduce how much food is eaten[7][8]. By imitating that hormone, Cagrilintide engages amylin (and related calcitonin) receptors to curb appetite and support weight management[2][9].

Activating these amylin pathways promotes satiety and delays gastric emptying, which together lower calorie intake; the effect may also complement insulin in steadying blood glucose[7]. Slower gastric emptying is part of why fullness lasts longer between meals.
Its long action profile supports a single weekly subcutaneous dose, holding steady exposure between injections and making once-weekly administration practical[3].
In a phase 2 dose-finding trial, once-weekly Cagrilintide produced clinically meaningful weight loss — about 10.8% at the 4.5 mg dose over 26 weeks — with gastrointestinal effects the most common adverse events[1].
Cagrilintide is also studied in combination with semaglutide (the investigational pairing known as “CagriSema”), where trials have reported substantial weight reductions beyond either agent alone[5][6]. It is an investigational compound presented here for research and educational purposes only and is not approved for general human use.

Lifestyle Factors

Habits that work alongside the protocol to protect results and ease the transition.

▪Nutrition: Eat a balanced, protein-forward diet (1.0–1.2 g/kg body weight) to hold on to lean mass while losing weight[10].
▪Hydration: Keep fluids up, particularly while titrating, when GI effects peak.
▪Physical activity: Pair resistance training (2–3×/week) with moderate cardio to aid metabolic adaptation and protect muscle.
▪Sleep & stress: Aim for 7–9 hours of solid sleep and manage stress to support hormonal balance and stay on track.
▪Meal timing: Smaller, more frequent meals help some people handle GI effects during early titration.

Potential Benefits & Side Effects

What dose-finding and combination trials have reported; individual results vary.

▪Appetite regulation: Stronger, longer-lasting satiety that helps reduce calorie intake[7][8].
▪Weight loss: About 10.8% body-weight reduction at 4.5 mg over 26 weeks in phase 2[1].
▪Metabolic support: May complement insulin activity and help stabilize blood glucose[7][9].
▪Convenient dosing: A single weekly subcutaneous dose is easier to keep up than daily regimens[3].
▪Gastrointestinal effects: Nausea, stomach upset, and related GI symptoms are the most common; usually mild-to-moderate and easing over time[1].
▪Slow titration helps: Starting low and stepping up gradually reduces early GI events[1].
▪Injection site reactions: Mild redness, swelling, or soreness can show up; rotating sites keeps it minimal.
▪Other: Occasional dizziness or headache have been reported; consult a professional if concerns arise.

Injection Technique

Subcutaneous injection technique, following established clinical practice and CDC guidance[13][14].

▪Wash your hands well with soap and water[14].
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Pick a site (abdomen, thigh, or upper arm) and wipe it with a fresh alcohol swab, letting it dry fully[13].
▪Carefully draw the intended dose, then check for air bubbles and push any out.
▪Pinch about a 1-inch fold of skin between thumb and forefinger[15].
▪Insert the needle into the pinch at a 90-degree angle (45 degrees if the fat layer is thin)[13][14].
▪Skip aspiration for subcutaneous shots — it isn’t needed and can add discomfort[13].
▪Press the plunger slowly and steadily until it’s fully down.
▪Pull the needle straight out and, if needed, press lightly with clean gauze.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle[14].
▪Put the reconstituted vial back in the fridge right away.
▪Shift the site each week (at least 1 inch over) to prevent lipohypertrophy[15].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for Cagrilintide 10mg.

Cagrilintide (10mg Vial) Dosage Protocol Open source
1 The Lancet (2021) Once-weekly cagrilintide for weight management: phase 2 dose-finding trial (Lau et al.) — ~10.8% weight loss at 4.5 mg over 26 weeks View Source ↗ Open source
2 New England Journal of Medicine (2025) REDEFINE 1: co-administered cagrilintide and semaglutide in adults with overweight or obesity View Source ↗ Open source
3 Clinical Pharmacokinetics (PMC, 2024) Clinical pharmacokinetics of cagrilintide and long-acting amylin analogues (dosing and half-life) View Source ↗ Open source
4 Journal of Medicinal Chemistry (2021) Discovery and development of cagrilintide, a long-acting amylin analogue View Source ↗ Open source
5 The Lancet (2021) Cagrilintide plus semaglutide phase 1b trial: safety, tolerability and pharmacokinetics (Enebo et al.) View Source ↗ Open source
6 New England Journal of Medicine (2025) REDEFINE 2: cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes View Source ↗ Open source
7 Brain Research Reviews (2005) Pancreatic amylin as a centrally acting satiating hormone (mechanism of appetite control) View Source ↗ Open source
8 PMC (2016) Amylin-mediated control of glycemia, energy balance and satiety View Source ↗ Open source
9 Int J Mol Sci (2024) Amylin, an important neuroendocrine hormone in metabolic and weight regulation View Source ↗ Open source
10 Journal of Cachexia, Sarcopenia and Muscle (PMC) Protein requirements during weight loss: preserving lean mass View Source ↗ Open source
11 GenScript Peptide storage and handling guidelines (lyophilized and reconstituted peptides) View Source ↗ Open source
12 Bachem Handling and storage guidelines for peptides (stability and freeze–thaw cycles) View Source ↗ Open source
13 Centers for Disease Control and Prevention (CDC) Vaccine administration: subcutaneous injection technique, angle and site guidance View Source ↗ Open source
14 NCBI Bookshelf Injection administration best practices (aseptic technique and sharps disposal) View Source ↗ Open source
15 Pharmacologic Considerations of the Subcutaneous Route (PMC) Subcutaneous injection technique and site rotation to prevent lipohypertrophy View Source ↗ Open source
16 Prime Lab Peptides Research peptide supplier (quality documentation and certificates of analysis) View Source ↗ Open source

Contents